Ease supply curbs on COVID vaccine raw materials, Indian think tank heads urge Biden administration

-

With an unprecedented COVID-19 crisis raging across India, a group of Indian think tanks have urged the United States to ease the global vaccine supply chain.

The article, addressed to the Biden administration, was written by Arvind Gupta, director of the Vivekananda International Foundation, Rudra Chaudhuri, director of Carnegie India, Harsh Pant, director of studies and the head of the Strategic Studies Programme at the Observer Research Foundation, Reuben Abraham, CEO of the IDFC Foundation and IDFC Institute, and Nitin Pai, co-founder and director of the Takshashila Institution.

The authors urged the US administration to “consider exceptions” to the Defense Production Act (DPA) of 1950, under which Washington has halted the export of raw materials critical for the production of COVID-19 vaccines.

While the DPA was first invoked by Donald Trump in early 2020, it continues to be in force during the term of Joe Biden.

This issue received global attention in recent days after Adar Poonawalla, CEO of the Serum Institute of India (SII), tagged Biden in a tweet.

Further, the group, noting that India is currently facing an 'acute vaccine shortage', said, "Making sure that the tens of millions of Indians are able to access vaccines is the only way in which a country as geographically challenging as India will be able to turn the tables on this fast-moving disease."

The article also said that the Serum Institute of India, which manufactures the Covishield vaccine in India, is hamstrung in its efforts to produce vaccines for both the Indian and global markets, and sought relaxations on the supply of items such as "bags and filters, cell culture media, single-use tubing assemblies, and other raw materials".

"It is crucial to keep in mind that without these ingredients, it is increasingly unlikely that the Serum Institute will be able to prioritise vaccine production under contract — through global vaccine alliances such as Gavi — for countries across the world," it said.

However, several reports have said that restrictions under DPA will only affect the production of the Novavax vaccine (marketed as Covovax in India) by the Serum Institute and not the Covishield (Oxford-AstraZeneca) vaccine.

The article also remarked, "India is a partner of the United States like none other. Today, it is a country in need of a more supportive American approach to supply chains. This is a request to the United States administration to seriously, urgently, and actively consider exceptions to the DPA. Such action will, in time, not only save lives in India and other large parts of the world that have been reliant on vaccines manufactured in India, but will also reassure the world’s largest democracy of the promise of a truly global America."

"The United States has adequate supplies and more. It is now time to relax the prioritisation measures and products that fall under the purview of the DPA,” they added.

According to official data updated on Saturday, a record single-day rise of 3,46,786 coronavirus cases pushed India's tally of infection to 1,66,10,481, while active cases crossed the 25-lakh mark.

The death toll rose to 1,89,544 with a record 2,624 more fatalities in a day, the data updated at 8 am showed.

With inputs from PTI



from Firstpost India Latest News https://ift.tt/32LqM6e
FP Staff

Comments

Post a Comment

Popular posts from this blog

Both COVID-19 vaccine doses needed for good protection against B16172 variant

-
It’s been a concerning few weeks in the UK, with the B16172 variant first taking hold and then spreading to become dominant. This more infectious form of the virus, initially identified in India, is what we’re now going to have to live with – unless it is out-competed by another variant in the future. Worryingly, experts had predicted that B16172 might be able to escape some of the effects of vaccines, which if true would threaten to derail the UK’s plans to finish lifting restrictions from the end of June. However, Public Health England (PHE) has looked at the ability of various variants to evade immunity and says that the UK’s vaccines remain effective against the variants circulating, including B16172. On the surface, this looks like good news. But delve a bit deeper, and things get more complicated, says Paul Hunter, professor of medicine at the University of East Anglia. PHE’s research found a little drop-off in protection against B16172 among people who were fully vaccinated.
Read more

New coronavirus variant emerge in India: How should our COVID response change?

-
Image
After genome sequencing of over 10,000 COVID-19 cases in India, researchers have discovered a new variant with two new mutations which may be better at evading the immune system. In 15-20 percent of samples from the Indian state of Maharashtra (the state accounting for 62 percent of cases in the country) a new, double mutation in key areas of the virus has been detected. These are now known as the E484Q and L452R mutations. What makes the variant different? Both these mutations are concerning because they are located in a key portion of the virus – the spike protein – that it uses to penetrate human cells. Spike proteins attach via a “receptor binding domain”, meaning the virus can attach to receptors in our cells. These new mutations include changes to the spike protein that make it a “better fit” for human cells. This means the virus can gain entry more easily and multiply faster. Given what we have seen with other similar mutations , it might also make it harder for our immu
Read more

Aditya L1 Mission: Spacecraft is nearing its final phase, says ISRO chief

-
Aditya L1 spacecraft is nearing its final phase, and manoeuvres to enter the L1 point are expected to be completed by January 7, 2024, according to ISRO Chairman S Somanath. “Aditya is on the way. I think it has reached almost its final phase,” the ISRO chief told PTI on the sidelines of an event organised at VSSC to commemorate the 60th year of the First Sounding Rocket Launch. Aditya L1, India’s first space-based mission to study the Sun, was successfully launched on September 2 from the Satish Dhawan Space Centre (SDSC) in Sriharikota. The spacecraft, after travelling about 1.5 million km from Earth over 125 days, is expected to be placed in a Halo orbit around the Lagrangian point L1, considered closest to the Sun. He said that the last preparations for the spacecraft’s entry into the L1 point are currently underway incrementally.”Possibly by January 7th, the final manoeuvres will be done for entering into the L1 point,” Somanath added. Among other tasks, it will capture and tr
Read more